{"id":193059,"date":"2023-04-13T00:00:00","date_gmt":"2023-04-13T00:00:00","guid":{"rendered":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/"},"modified":"2023-04-13T00:00:00","modified_gmt":"2023-04-13T00:00:00","slug":"aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting","status":"publish","type":"post","link":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/","title":{"rendered":"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting"},"content":{"rendered":"

Aspect Biosystems and Novo Nordisk A\/S have entered a collaboration, development, and licensing agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body, with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect\u2019s proprietary bioprinting technology and Novo Nordisk\u2019s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.<\/p>\n

Under the terms of the agreement, Novo Nordisk will receive an exclusive, worldwide license to use Aspect\u2019s bioprinting technology to develop up to four products for the treatment of diabetes and\/or obesity. Aspect will receive initial payments of $75 million, including an upfront payment, research funding, and an investment in the form of a convertible note. Aspect is also eligible to receive up to $650 million in future development, regulatory, commercial, and sales milestone payments per product, as well as tiered royalties on future product sales.<\/p>\n

\u201cWe are thrilled to part<\/a>ner with Novo Nordisk, a global leader and pioneer in the fight against diabetes and chronic diseases, to create breakthrough therapeutics that could transform the lives of millions of people around the world,\u201d said Tamer Mohamed, chief executive officer of Aspect Biosystems. \u201cThis part<\/a>nership leverages Aspect\u2019s full-stack tissue therapeutic platform, talented team, and bold vision, and reinforces our strategy to create bioprinted tissue therapeutics through part<\/a>nerships with global industry leaders while also advancing our internal therapeutic pipeline.\u201d<\/p>\n

\n
\n

Manufacturing on Demand<\/h4>\n
Order custom parts through our online manufacturing network. Low cost, fast delivery. Upload your design for free quotes now!<\/div>\n<\/div>\n

<\/i> Get Quote<\/a><\/div>\n

Novo Nordisk headquart<\/a>ers, in Denmark. <\/p>\n

Aspect Biosystems has developed a platform technology that may allow for the development of a novel class of cell-based medicine designed to be biologically functional, encapsulated to be immune-protective, and suitable for surgical implantation. Novo Nordisk has developed expertise to differentiate stem cells into a wide array of cells that may be used to replace damaged and lost cells (which could lead to a specific disease, such as insulin-producing beta cells in type 1 diabetes, as well as manufacturing capabilities to produce the cells at scale).<\/p>\n

By combining the strongholds of each company, the collaboration aims to develop implantable bioprinted tissues to replace, repair, or supplement biological functions. These tissues will be designed to be allogeneic \u2013 meaning the cells used are derived from a single source to increase the viability of future large-scale manufacturing.<\/p>\n

\u201cNovo Nordisk has built strong capabilities when it comes to producing functional and highly pure therapeutic replacement cells at the highest quality and at scale,\u201d said Jacob Sten Petersen, corporate vice president of Cell Therapy R&D at Novo Nordisk. \u201cCollaborating with Aspect Biosystems adds an important component to our strategy to develop comprehensive cell therapy products. We are excited to co-develop solutions for cell therapy delivery that could lead to life-changing treatments for those living with a serious chronic disease.\u201d<\/p>\n

The collaboration will initially focus on developing bioprinted tissue therapeutics designed to maintain normal blood glucose levels without the need for immunosuppression, which may represent a transformative treatment for people living with type 1 diabetes.<\/p>\n

\n
You might also like:<\/h5>\n

Atelier des Refus\u00e9s and Stratasys create 3D printed decorative pillows: <\/a>The pair share common ground in their commitment to sustainability. Atelier des Refus\u00e9s, named after the historic Parisian Salon des Refus\u00e9s, is on a mission to give value to the concept of waste by using high-quality fabrics to create one-of-a-kind decorative cushions.<\/p><\/blockquote>\n

* This article is reprinted from 3D Printing Media Network<\/a>. If you are involved in infringement, please contact us to delete it.<\/p>\n

<\/i> Author: Edward Wakefield<\/p>\n","protected":false},"excerpt":{"rendered":"

Aspect Biosystems and Novo Nordisk A\/S have entered a collaboration, development, and licensing agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body, with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect\u2019s proprietary bioprinting technology and Novo Nordisk\u2019s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.<\/p>\n","protected":false},"author":3,"featured_media":193061,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"fifu_image_url":"\/news\/wp-content\/uploads\/2023\/05\/6321559470702646630.jpeg","fifu_image_alt":"","footnotes":""},"categories":[285],"tags":[4046,5123],"class_list":["post-193059","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-acquisitions","tag-mergers-partnershipsbioprintingdrug-discovery-development"],"yoast_head":"\nAspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting - FacFox News<\/title>\n<meta name=\"description\" content=\"Aspect Biosystems and Novo Nordisk A\/S have entered a collaboration, development, and licensing agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body, with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect\u2019s proprietary bioprinting technology and Novo Nordisk\u2019s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting\" \/>\n<meta property=\"og:description\" content=\"Aspect Biosystems and Novo Nordisk A\/S have entered a collaboration, development, and licensing agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body, with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect\u2019s proprietary bioprinting technology and Novo Nordisk\u2019s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/\" \/>\n<meta property=\"og:site_name\" content=\"FacFox News\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"\/news\/wp-content\/uploads\/2023\/05\/6321559470702646630.jpeg\" \/><meta property=\"og:image\" content=\"\/news\/wp-content\/uploads\/2023\/05\/6321559470702646630.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Vera\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"\/news\/wp-content\/uploads\/2023\/05\/6321559470702646630.jpeg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vera\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/\"},\"author\":{\"name\":\"Vera\",\"@id\":\"https:\/\/facfox.com\/news\/#\/schema\/person\/7b701aad2d8f434034fcecd2c50a570c\"},\"headline\":\"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting\",\"datePublished\":\"2023-04-13T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/\"},\"wordCount\":614,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/facfox.com\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/facfox.com\/news\/wp-content\/uploads\/2023\/05\/d7745e5b4b80b566178fd64cf8521eb5.jpg\",\"keywords\":[\"Acquisitions\",\"Mergers & PartnershipsBioprintingDrug Discovery & Development\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/\",\"url\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/\",\"name\":\"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting - FacFox News\",\"isPartOf\":{\"@id\":\"https:\/\/facfox.com\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/facfox.com\/news\/wp-content\/uploads\/2023\/05\/d7745e5b4b80b566178fd64cf8521eb5.jpg\",\"datePublished\":\"2023-04-13T00:00:00+00:00\",\"description\":\"Aspect Biosystems and Novo Nordisk A\/S have entered a collaboration, development, and licensing agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body, with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect\u2019s proprietary bioprinting technology and Novo Nordisk\u2019s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.\",\"breadcrumb\":{\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#primaryimage\",\"url\":\"https:\/\/facfox.com\/news\/wp-content\/uploads\/2023\/05\/d7745e5b4b80b566178fd64cf8521eb5.jpg\",\"contentUrl\":\"https:\/\/facfox.com\/news\/wp-content\/uploads\/2023\/05\/d7745e5b4b80b566178fd64cf8521eb5.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/facfox.com\/news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/facfox.com\/news\/#website\",\"url\":\"https:\/\/facfox.com\/news\/\",\"name\":\"FacFox News\",\"description\":\"News and Insights of 3D Printing and Manufacturing\",\"publisher\":{\"@id\":\"https:\/\/facfox.com\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/facfox.com\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/facfox.com\/news\/#organization\",\"name\":\"FacFox News\",\"url\":\"https:\/\/facfox.com\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/facfox.com\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/facfox.com\/news\/wp-content\/uploads\/2020\/11\/facfox-news-homepg-logo-200px.png\",\"contentUrl\":\"https:\/\/facfox.com\/news\/wp-content\/uploads\/2020\/11\/facfox-news-homepg-logo-200px.png\",\"width\":200,\"height\":55,\"caption\":\"FacFox News\"},\"image\":{\"@id\":\"https:\/\/facfox.com\/news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/facfox.com\/news\/#\/schema\/person\/7b701aad2d8f434034fcecd2c50a570c\",\"name\":\"Vera\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/bf3b1e47e1f0ed2367da10e343584d5a4adb2e9675fce2aefb04f0ecf3954386?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bf3b1e47e1f0ed2367da10e343584d5a4adb2e9675fce2aefb04f0ecf3954386?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bf3b1e47e1f0ed2367da10e343584d5a4adb2e9675fce2aefb04f0ecf3954386?s=96&d=mm&r=g\",\"caption\":\"Vera\"},\"url\":\"https:\/\/facfox.com\/news\/author\/vera\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting - FacFox News","description":"Aspect Biosystems and Novo Nordisk A\/S have entered a collaboration, development, and licensing agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body, with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect\u2019s proprietary bioprinting technology and Novo Nordisk\u2019s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/","og_locale":"en_US","og_type":"article","og_title":"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting","og_description":"Aspect Biosystems and Novo Nordisk A\/S have entered a collaboration, development, and licensing agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body, with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect\u2019s proprietary bioprinting technology and Novo Nordisk\u2019s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.","og_url":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/","og_site_name":"FacFox News","article_published_time":"2023-04-13T00:00:00+00:00","og_image":[{"url":"\/news\/wp-content\/uploads\/2023\/05\/6321559470702646630.jpeg","type":"","width":"","height":""},{"url":"\/news\/wp-content\/uploads\/2023\/05\/6321559470702646630.jpeg","width":1,"height":1,"type":"image\/jpeg"}],"author":"Vera","twitter_card":"summary_large_image","twitter_image":"\/news\/wp-content\/uploads\/2023\/05\/6321559470702646630.jpeg","twitter_misc":{"Written by":"Vera","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#article","isPartOf":{"@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/"},"author":{"name":"Vera","@id":"https:\/\/facfox.com\/news\/#\/schema\/person\/7b701aad2d8f434034fcecd2c50a570c"},"headline":"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting","datePublished":"2023-04-13T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/"},"wordCount":614,"commentCount":0,"publisher":{"@id":"https:\/\/facfox.com\/news\/#organization"},"image":{"@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#primaryimage"},"thumbnailUrl":"https:\/\/facfox.com\/news\/wp-content\/uploads\/2023\/05\/d7745e5b4b80b566178fd64cf8521eb5.jpg","keywords":["Acquisitions","Mergers & PartnershipsBioprintingDrug Discovery & Development"],"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/","url":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/","name":"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting - FacFox News","isPartOf":{"@id":"https:\/\/facfox.com\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#primaryimage"},"image":{"@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#primaryimage"},"thumbnailUrl":"https:\/\/facfox.com\/news\/wp-content\/uploads\/2023\/05\/d7745e5b4b80b566178fd64cf8521eb5.jpg","datePublished":"2023-04-13T00:00:00+00:00","description":"Aspect Biosystems and Novo Nordisk A\/S have entered a collaboration, development, and licensing agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body, with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect\u2019s proprietary bioprinting technology and Novo Nordisk\u2019s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.","breadcrumb":{"@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#primaryimage","url":"https:\/\/facfox.com\/news\/wp-content\/uploads\/2023\/05\/d7745e5b4b80b566178fd64cf8521eb5.jpg","contentUrl":"https:\/\/facfox.com\/news\/wp-content\/uploads\/2023\/05\/d7745e5b4b80b566178fd64cf8521eb5.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/facfox.com\/news\/aspect-biosystems-and-novo-nordisk-enter-bioprinted-tissue-therapeutics-partnership-bioprinting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/facfox.com\/news\/"},{"@type":"ListItem","position":2,"name":"Aspect Biosystems and Novo Nordisk enter bioprinted tissue therapeutics partnership Bioprinting"}]},{"@type":"WebSite","@id":"https:\/\/facfox.com\/news\/#website","url":"https:\/\/facfox.com\/news\/","name":"FacFox News","description":"News and Insights of 3D Printing and Manufacturing","publisher":{"@id":"https:\/\/facfox.com\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/facfox.com\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/facfox.com\/news\/#organization","name":"FacFox News","url":"https:\/\/facfox.com\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/facfox.com\/news\/#\/schema\/logo\/image\/","url":"https:\/\/facfox.com\/news\/wp-content\/uploads\/2020\/11\/facfox-news-homepg-logo-200px.png","contentUrl":"https:\/\/facfox.com\/news\/wp-content\/uploads\/2020\/11\/facfox-news-homepg-logo-200px.png","width":200,"height":55,"caption":"FacFox News"},"image":{"@id":"https:\/\/facfox.com\/news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/facfox.com\/news\/#\/schema\/person\/7b701aad2d8f434034fcecd2c50a570c","name":"Vera","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/bf3b1e47e1f0ed2367da10e343584d5a4adb2e9675fce2aefb04f0ecf3954386?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bf3b1e47e1f0ed2367da10e343584d5a4adb2e9675fce2aefb04f0ecf3954386?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bf3b1e47e1f0ed2367da10e343584d5a4adb2e9675fce2aefb04f0ecf3954386?s=96&d=mm&r=g","caption":"Vera"},"url":"https:\/\/facfox.com\/news\/author\/vera\/"}]}},"fifu_image_url":"\/news\/wp-content\/uploads\/2023\/05\/6321559470702646630.jpeg","_links":{"self":[{"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/posts\/193059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/comments?post=193059"}],"version-history":[{"count":0,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/posts\/193059\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/media\/193061"}],"wp:attachment":[{"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/media?parent=193059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/categories?post=193059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/facfox.com\/news\/wp-json\/wp\/v2\/tags?post=193059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}